Pills, courtesy of Higlu on Flickr
UCL and the Japanese pharmaceutical company Eisai, have entered into a new agreement to establish a major drug discovery and development collaboration today. The alliance will involve researchers from both organisations working together to investigate radical new ways of treating neurological diseases such as Alzheimer's, Parkinson's and other related disorders. The goal of the collaboration will be to identify and validate novel drug targets, develop new therapeutics and evaluate them in proof-of-concept clinical trials. UCL and Eisai will form a Therapeutic Innovation Group (TIG) which will comprise experienced scientists from both UCL and Eisai with the principal function of facilitating and coordinating the discovery and assessment of emerging therapeutictargets involved in neurological diseases. Research is expected to be carried out at UCL's new Leonard Wolfson Experimental Neurology Centre, while Eisai will provide drug discovery and development resource and know-how, assay development capabilities and medicinal chemistry expertise. If successful, UCL will also receive milestone and royalty payments on therapies brought to market through the collaboration. "Neurological disorders such as Alzheimer's and Parkinson's disease represent a significant unmet medical need due to lack of effective treatments that can prevent disease progression," said Lynn Kramer, President of the Eisai Neuroscience Product Creation Unit.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
